INTRODUCTION
The redox properties of Cu + endow the metal with the simultaneous ability to be both essential and potentially damaging to the cell. Thus, as the cell only needs Cu + in trace amounts, to counter the relative high levels of Cu + in the environment and food, animals have developed sophisticated mechanisms to chaperone, store and eliminate excess Cu + . In the liver, the hepatocyte acts as the major captor of the Cu + absorbed in the digestive tract, the main reservoir and distributor of Cu + to other tissues and organs as well as the key mediator of Cu + elimination by excretion in the bile (Harris, 2000; Lalioti et al., 2009 ). Because of these three functionalities the liver plays an essential role in Cu + homeostasis in mammals, birds and reptiles.
In the hepatocyte, the elimination of Cu + is mediated by ATP7B, a membrane pump specialized for the vectorial transport of Cu + (Bull et al., 1993; Tanzi et al., 1993) . At physiological concentrations of Cu + , ATP7B is localized to the trans-part of the Golgi apparatus where it functions in the transfer of Cu + to secretory proteins such as ceruloplasmin. Increased Cu + levels in the hepatocyte results in the release of the ATP7B sequestered in the trans-Golgi network (TGN) and its relocation to other membrane compartments. However, though the direct relocalization of ATP7B to the bile canaliculus (BC) would appear to be the most likely trafficking route (Guo et al., 2005; Hernandez et al., 2008; Roelofsen et al., 2000b) , studies on the Cu + -induced relocation of ATP7B have resulted in identification of other membrane targets, including late endosomes and lysosomes (Harada et al., 2003a; Polishchuk et al., 2014; al., 2014) . These observations are in contrast with studies indicating that ATP7B is transported from the Golgi to the BC and recent evidence indicating that transport to the BC occurs through a trans-endosomal pathway (Lalioti et al., 2014; Nyasae et al., 2014) .
While more than 300 mutations in the ATP7B gene affecting the function and cellular distribution of ATP7B have been associated with the Wilson disease, a rare autosomal Cu + toxicosis (Kenney and Cox, 2007) , the tight association between the traffic and function of ATP7B in Cu + donation and elimination makes it likely that some Cu + metabolism abnormalities could be caused by the dysfunction of the mechanisms of membrane protein traffic and their regulation, dysfunction that may also affect the traffic of other proteins. With regard to this, it is interesting that mutation of the AP1S1 gene, which codes for the σ1A subunit of the clathrin adaptor AP-1 involved in the intracellular trafficking of Cu + transporters ATP7B and ATP7A (Holloway et al., 2013; Jain et al., 2015; Lalioti et al., 2014) , causes the MEDNIK syndrome described as a new disorder of copper metabolism (Martinelli et al., 2013) . Furthermore, deficiency of the COMMD1, a protein component of the CCC complex that plays an important role in the trafficking of retromer cargo, results in defective Cu + homeostasis (Phillips-Krawczak et al., 2015; van De Sluis et al., 2002) .
It is thus important to characterize the traffic pathway of ATP7B in the hepatocyte and the site of ATP7B action, not only to enable the identification of the genetic defects associated with Cu + toxicosis, but also to understand the presentation and course of those disorders, and to design specific strategies to prevent and treat them.
We describe here the characterization of the Cu + -dependent pathway of ATP7B translocation from the TGN to the BC in the polarized rat hepatoma Can 10 cell. Our results indicate that on Cu + -induced release from the trans-Golgi network, ATP7B is initially sorted to the basolateral membrane and then transported by transcytosis to the BC via a route that includes the subapical compartment and excludes the lysosomes.
RESULTS
Polarized hepatoma Can 10 cells use the inwards-positioned apical surface to assemble BC of different sizes and, when growing in small islets, arrange their bodies perpendicular to the BC and project their large basolateral surface outwards ( Fig. S1A-D ) (Cassio et al., 2007; Hernandez et al., 2008) , this arrangement greatly facilitates to monitoring the changes in the distribution of ATP7B in response to increased Cu + levels in the cell.
ATP7B IS BASOLATERAL SORTED at the TGN by ACIDIC VESICLES.
Careful titration of the Cu + dose/ATP7B response in Can 10 cells showed that additions of Cu + >1 µM to the cell medium caused the mobilization of the ATP7B retained in the TGN at low Cu + concentrations . To study the pathway of ATP7B translocation from the TGN to the BC we used 40 µM Cu + , concentration that caused the fast release of ATP7B from the TGN and a traffic rate suitable to monitor the redistribution of ATP7B and to characterize the pathway of transport.
ATP7B began to leave the TGN within 5 min after addition of Cu + and the release was completed in 15-20 min ( Fig. 1A1-C2 ). The acidic pH of the TGN led us to study if increase in the pH affected the ATP7B release. To this end, we studied the release of ATP7B from the TGN in Can 10 cells preincubated for 3h with 50 µM chloroquine (CQ), an acidotropic agent that accumulates in acidic organelles, producing the loss of their acidity and their osmotic swelling.
The study revealed that 15 min after the addition of Cu + many of the vesicles transporting ATP7B out of the Golgi remained attached to the TGN and were swollen, hence indicating that the acidity of the TGN was critical for the release of the vesicles loaded with ATP7B (Fig. 1D1 ). ATP7B at the far end of the basolateral domain, opposite to the BC, was consistent with the step of ATP7B through basolateral endosomes after its release from the TGN ( Fig. 2C1-C3 ; Table   S1 ).
BASOLATERAL SORTED ATP7B is not INCORPORATED into LYSOSOMES.
The acidity of the vesicles loaded with ATP7B that pinch-off from the TGN and the reported ability of Cu + to induce the direct and fast incorporation of ATP7B into late endosomes/ lysosomes (Polishchuk et al., 2014) , prompted us to examine those vesicles and the incorporation of ATP7B into lysosomes during the ATP7B relocation to basolateral endosomes.
To this end and to minimize the chances that ATP7B would be incorporated into a discrete/small population of lysosomes, causing the event to pass unnoticed, we separately compared the distributions of ATP7B and four lysosomal integral membrane proteins (LIMPs), CD63, LIMPII, LAMP1 and LAMP2, which are unevenly distributed among late endosomes, plasma membrane, specialized phagosomes and secretory vesicles (Figs. 3A) (Barriocanal et al., 1986; Metzelaar et al., 1991 (Polishchuk et al., 2014) . Altogether these data indicated that the vesicles that transported ATP7B through the basolateral domain were structures distinct from lysosomes.
ATP7B IS INSERTED INTO the BASOLATERAL MEMBRANE and ENDOCYTOSED.
To know if the presence of ATP7B in basolateral endosomes resulted from the fusion of endosomes with the vesicles that transported ATP7B to the basolateral domain, or from the ATP7B insertion into the basolateral membrane and subsequent endocytosis, we studied the effect of dynasore (DYN), the inhibitor of dynamin and clathrin-dependent endocytosis, and Moreover, in cells transfected with exofacially HA-tagged ATP7B we localized the endocytosed HA antibody and Alexa647-Tf in endosomes transporting ATP7B (Fig. 4C1-C3 ). These two studies strongly indicated that after its release from the TGN, ATP7B was targeted to the basolateral domain and inserted into the basolateral membrane, and was then endocytosed.
To investigate if ATP7B interacted with AP-2, the clathrin adaptor that works in cargo internalization by clathrin-mediated endocytosis. To this end we examined the ability of ATP7B
and the α subunit of the AP-2 adaptor to pull each other down (Fig. 4D) . Confirmation of this ability suggested that the surface localized AP-2 worked in the clathrin-mediated endocytosis of ATP7B inhibited by DYN.
ATP7B is VECTORIALLY TRANSPORTED from the BASOLATERAL to the APICAL DOMAIN by a MECHANISM that REQUIRES MICROTUBULES.
To examine the redistribution of the basolateral endosomes loaded with ATP7B and Tf, we Table S1 ). It is well established that vesicle-mediated transcytosis from the basolateral to the apical domain requires microtubules (Hunziker et al., 1990) . To explore if transport of ATP7B to the apical pole required microtubules, we incubated Can 10 cells for 15 min with Cu + , to target the ATP7B retained in the TGN to the basolateral domain, and then for 60 min at 4ºC with the microtubule inhibitor nocodazol (NOC) before incubation for 40 min at 37ºC with or without NOC and with Alexa 647-Tf, in the continuous presence of Cu + (Fig. 5) . The results showed that in cells warmed in NOC, and therefore without microtubules, the translocation of ATP7B to the apical domain was strongly inhibited and the protein was retained in numerous vesicles dispersed throughout the cytoplasm, many of them loaded with Tf ( Fig. 5B1-B5 ). In contrast, the washing of NOC immediately before warming of the cells, resulted in complete reconstruction of the microtubule network and in translocation of ATP7B to the apical BC ( Fig. 5C1-C5 ). Table S7 ), and analysis of the experimental data using a geometric distribution that allows the estimation of the probability to detect one LIMP signal in the SAC , produced a pSAC < 0.049 ( = 0.033) at a 95% confidence level that strongly endorsed the experimental observations ( Fig.   S3B , Table S7 ).
ATP7B ENTERS THE SUBAPICAL

TRANSPORT OF ATP7B FROM THE APICAL POLE to the BILE CANALICULUS is INHIBITED by the
ARF-GEF INHIBITOR, BREFELDIN A
The fungal toxin brefeldin A (BFA) specifically targets the large ARFs, GTPAses which regulate trafficking pathways by recruiting the vesicle coat components AP-clathrin adaptors, COPI and GGA proteins (Cox et al., 2004) . with BFA/ NOC in the presence of the metal, before raising the temperature to 37ºC and continuing the incubation with the two drugs, with BFA alone and without drugs (Fig. 6 ). The results showed that whereas in cells incubated with NOC and BFA the ATP7B protein was retained in vesicles distributed throughout the cytoplasm (Fig. 6G1-G4) ; the removal of NOC allowed the advance of ATP7B to the apical area and its retention in SAC (Figs. 6H1-H4).
Moreover, removal of NOC and BFA resulted in incorporation of ATP7B into the BC (Fig. 6I1-I4 ).
We therefore concluded that BFA inhibited the transport of ATP7B from the SAC to the BC, probably by inhibiting apical BIG2. Our results were similar to those described for the transcytosis of the polymeric immunoglobulin receptor in polarized neurons, where BFA inhibited the redistribution of the receptor from the basal-dendritic domain to the apicalaxonal domain (de Hoop et al., 1995) . S4 ).
APICAL ENDOCYTOSIS OF ATP7B IS INHIBITED by DYN and RECYCLING by BFA.
Treatment of cells with the non-permeable Cu + chelating agent, bathocuproine disulphonate (BCS), induced only a slow return of ATP7B from the BC to the TGN, probably due to the requirement of functional ATP7B in the BC to feed extracellular BCS with excreted Cu + (Fig.   7D ). In contrast, the use of the cell permeable Cu + chelating agent neocuproine (NEC), to directly reduce intracellular Cu + , produced a more rapid transit and after a 2h incubation with the drug the bulk of ATP7B was returned to the TGN ( Fig. 7D ; compare Figs. 7E1-E4 and 7F1-F4).
In the experiments using NEC, we observed that DYN strongly inhibited the exit of ATP7B from the BC suggesting that the ATP7B was endocytosed by clathrin coated vesicles (compare Figs.7F1-F4 and 7H1-H4). In addition, we also observed that while organelle de-acidification, induced by BF, did not inhibit the apical endocytosis of ATP7B, it did inhibit its apical recycling and return to the TGN, retaining it in large vesicular bodies abundant in the subapical area adjacent to the BC (Fig. 8A1-C4 ). Since the treatment with BFA inhibited the target of ATP7B to the BC (Fig. 6H1-H4 ), we studied the possibility that the SAC was involved in the apical recycling of ATP7B by examining the distribution of ATP7B in cells that were first treated with Cu Figs. 6H1-H4 and Figs S2B1-C3 ). These results demonstrate that in cells with elevated levels of Cu + , the ATP7B transported from the TGN to the BC membrane was continuously endocytosed and cycled between the SAC and the BC.
DISCUSSION
In this study we have characterized the pathway of ATP7B transport from the TGN to the BC in response to the elevation of intracellular Cu + levels in the rat hepatoma cell line Can 10.
The Cu + induced release of ATP7B from the TGN was found to be a rapid process that begins within 5 min of the addition of 40 µM Cu + and is completed within 20-25 min. Treatment with BF delayed the detachment of the cisterna carrying ATP7B from the TGN, demonstrating that cisterna detachment is a prerequisite to the generation of transport vesicles as has previously been described in plants ( Uemura et al., 2014) . This process is pH dependent and the rapidity of his occurrence in mammalian cells is probably why it has not been previously observed in others than plants. Our studies also show that the vesicles loaded with ATP7B budding from the TGN do not contain lysosomal membrane proteins, suggesting that these are instead The accumulation of ATP7B in the SAC of cells incubated with BFA following its endocytosis from the basolateral membrane, together with its incorporation into the BC after removal of the drug, both implicate a large ARF-GEF localized in recycling endosomes, such as BIG2, in the targeting of ATP7B from the SAC to the BC. Our finding that BFA inhibits the recycling of apically endocytosed ATP7B to the BC by retaining the protein in the SAC suggests that the same mechanisms of transport that operate in the SAC may function in both the transcytosis of ATP7B and in its apical recycling.
The inhibition of apical ATP7B endocytosis by DYN is consistent with the BC being the site of ATP7B functioning in Cu + excretion. It should be noted that this observation is confirmatory of the originally observed Cu + -induced translocation of ATP7B from the TGN to the BC in HepG2 cells and the localization of ATP7B in the BC of liver (Guo et al., 2005; Roelofsen et al., 2000a; Schaefer et al., 1999b) , and that these studies were subsequently confirmed in other cells by other laboratories (Guo et al., 2005) 5; (Hernandez et al., 2008) .
Is intriguing to note that while most of the membrane proteins, resident in the BC, that contain multiple transmembrane spanning sequences are directly targeted from the Golgi (Kipp and Arias, 2002), ATP7B in contrast uses a distinct transcytosis route to reach the BC, a route that was previously thought to be restricted to apical proteins with a single transmembrane domain (Bastaki et al., 2002) .
The conclusions of the studies reported here are in contrast with those of a recent study in HepG2 cells that proposes that ATP7B is rapidly and directly targeted from the TGN to lysosomes in response to Cu + and that fusion of the Cu + loaded lysosomes with the BC membrane results in the excretion of excess Cu + into the bile (Polishchuk et al., 2014) . The latter studies extended previous reports that interpreted the presence and functioning of transfected GFP-ATP7B and ATP7B-DsRed constructs in late endosomes as part of the lysosome-mediated excretion of Cu + into the bile. In these studies the ATP7B constructs were not detected in the TGN and were not relocated in response to excess Cu + (Harada et al., 2005; Harada et al., 2003b; Harada et al., 2000a; Harada et al., 2000b) . In contrast, in our studies in highly polarized Can 10 cells we observe that excess Cu + induces the rapid translocation of endogenous ATP7B from the TGN to the BC by basolateral sorting and transcytosis. Moreover, during this rapid trafficking process we did not find any association of ATP7B with lysosomes and, repeating these studies using HepG2 cells we could not find any ATP7B in the lysosomes in response to Cu + treatment in these cells. Furthermore, we did not observe any Cu + -induced movement of lysosomes towards the BC, nor did we detect any incorporation of four distinct LIMPs into the BC as it would be expected if the excretion of Cu + was primarily mediated by lysosomal exocytosis.
The picture emerging from studies in human and rat frozen sections of liver is that endogenous ATP7B is localized in the TGN and in the bile canaliculus (Schaefer et al., 1999a; Schaefer et al., 1999b) . However more studies are needed to establish the response of the ATP7B retained in the TGN to excess Cu + in liver. In closing, this study describes that the Cu + -dependent relocation of ATP7B from the TGN to the bile canaliculus includes the basolateral sorting at the TGN, transport to and endocytic retrieval at the basolateral membrane, followed by microtubule-dependent transcytosis through the SAC and incorporation into the BC. These results indicate that the site of ATP7B action in vectorial Cu + excretion is the membrane of the BC.
It is important that abnormal intracellular trafficking of the Cu
MATERIALS AND METHODS
CELL CULTURE
Rat hepatoma Can 10 and human hepatoma HepG2 cells were grown in Coon's modification medium supplemented with 1.5 g/L NaCO3H, 10% fetal calf serum, 1% glutamax penicillin and streptomycin (CS). Can 10 cells were cultured for 5-days for complete surface polarization and media was changed daily. Counting of basolateral vesicles was facilitated by growing the Can 10 cells in polylysine-coated coverglasses and incubating the cells for 10 h in Coon's medium supplemented with 0.5 mM 3-isobutyl-1-methylxanthine.
cDNA CLONING, CONSTRUCTS AND TRANSFECTIONS
Mouse ATP7B cDNA was cloned by PCR amplification of a mouse liver Marathon Ready cDNA library (Lalioti et al., 2014) . Exofacial HA-tagging of ATP7B was performed by introducing the tag into the third exofacial loop of ATP7B (Lalioti et al., 2014) . Cells were transfected for 11 h using Lipofectamine 2000 to minimize protein overexpression, and the last 3h were incubated with 50 µg/mL cycloheximide to inhibit new ATP7B synthesis.
ANTIBODIES
Polyclonal anti-ATP7B antibodies (Hernandez et al., 2008) , antibodies to TGN38 (Yuan et al., 1987) and the lysosomal membrane proteins CD63, LIMPII, LAMP1 and LAMP2 (Barriocanal et al., 1986) were developed in the laboratory. Further details on these antibodies and on other primary and secondary antibodies used in this study are provided in Additional Methods
CHEMICALS
Neocuproine (NEC), bathocuprine disulfonate (BCS) and brefeldin A (BFA) were from Sigma Aldrich (MO ; nocodazol (NOC) and dynasore (DYN) were from Santa Cruz Biotech.
IMMUNOFLUORESCENCE MICROSCOPY
Cell fixation was adapted to antibody reactivity; fixation/permeabilization was performed by treatment with cold (-20ºC) methanol for 4 min (anti-ATP7B, ZO-1,YOL 1/34,TGN38, β catenin CD63, LIMPII, LAMP1 and LAMP2 antibodies); for 20 min with 2% paraformaldehyde and 5 min with 0.2% Triton X100 (anti-ATP7B, Zo-1, Rab11a, YOL 1/34, HA tag and EEA1 antibodies) and for 1 min with 3% paraformaldehyde and 10 min with methanol at 5ºC (ATP7B, ZO-1 and HA4
antibodies). For co-localization studies, cells were grown on 0.1-0.16 mm glass coverslips and mounted in gelvatol (refractive index 1.376). Stable Alexa488 and Alexa647 dyes were used to avoid spectral bleed and the stained cells were examined using a Zeiss Plan-apochromat x63/1.4 oil DIC objective and oil with a refractive index of 1.51. Capture Images were deconvoluted and studied using Coloc 2 and JACoP modules of Image J software. Data was subjected to robust statistics (see Statistics Suppl. Exp. Proc.).
ATP7B TRAFFICKING ASSAYS.
The de-acidification agent BF, the dynamin inhibitor DYN, the microtubule inhibitor NOC, the ARF-GEF inhibitor BFA and incubation at low temperature were used to treat cells and help dissect the pathway of transport. Translocation of ATP7B from the TGN to the BC was studied by challenging Can 10 cells with 40 µM Cu + for periods between 5 min and 2h; the translocation process was best monitored in small islets organized by highly polarized cells.
The effective retention of ATP7B in the TGN at 0.3 µM Cu + made unnecessary the use of Cu + chelating agents to reset the start of the protein traffic at the TGN. In a set of traffic experiments we established as landmarks of the ATP7B anterograde traffic, the beginning (5-7 min) and completion (10-15 min) of its release from the Golgi; its appearance in basolateral endosomes loaded with endocytosed Tf (8-20 min); its approach and entrance into the SAC (15-35 min), and its incorporation into the BC (30 min-1h) (see Fig. 7C ). These landmarks helped to set a series of traps to dissect the pathway of ATP7B transport: bafilomycin -A1 (BF) and chloroquine (CQ) were employed to slowdown the release of ATP7B by acidic vesicles from the TGN; dynasor (DYN), the inhibitor of dynamin and clathrin-dependent endocytosis, was used at 80 µM in serum free media to exam the traffic of ATP7B through the basolateral membrane; nocodazol (NOC) the microtubule depolymerizing agent was a powerful tool to study the second leg of traffic between the basolateral membrane and the SAC and the incorporation of ATP7B into the BC; we incubated cells for 15 min with Cu + to target ATP7B from the TGN to basolateral endosomes, and then for 1h with Cu + , NOC and BFA, at 4ºC, to disrupt the microtubules and to set the stage to study the redistribution of basolateral ATP7B
after warming the cells in the absence of NOC, and the presence or absence of BFA; the trapping of ATP7B in the SAC of cells warmed up in the absence of NOC and in the presence of BFA, helped to characterized the passage of ATP7B through the SAC and indicated the involvement of a BFA-sensitive ARF-GEF in the regulation of the ATP7B target from the SAC to the BC, probably the apical BIG2; for studies of apical ATP7B endocytosis and retrograde transport the cell permeable neocupreine (NEC) was the Cu + chelating agent of choice for its quick effects in eliciting the backwards ATP7B traffic in response to decrease Cu + levels, the cell impermeable bathocuproine disulfonate (BCS) was less effective; DYN was a strong tool to study the apical endocytosis of ATP7B in cells deprived of Cu + by treatment with NEC, whereas BFA was effective in trapping the apically endocytosed ATP7B in cells continuously incubated with Cu + . The experiments were repeated an average of three times.
IMMUNOPRECIPITATION and WESTERN BLOT STUDIES.
All the procedures were performed at 4º C. Can 10 cells were washed twice with TBS, scraped, suspended in 1mL of cold buffer A (20mM HEPES pH 7.5, 130 mM NaCl, 1mM EGTA, and one tablet of the cocktail of protease inhibitors Complete Mini, Roche) and incubated in 1% NP40
for 10 min, and nuclei removed by centrifugation at 100x g for 10 min. The resulting postnuclear supernatant was incubated at 4ºC for 1h, aggregates removed by centrifugation at 15000 x g for 10 min, and dilution in buffer A to 0.6% NP40 by. Equal extract aliquots were separately incubated 4h with the rabbit anti-ATP7B antibody or the goat anti AP-2α antibody bound to Protein G-Sepharose, prepared by mixing 5 μL of each antibody with 15 μL of Protein G-Sepharose (GE Healthcare) and then washing off excess antibody. Immunoprecipitation complexes were collected by low-speed centrifugation and, after three washes in buffer A and one in water, were resuspended and heated (85ºC, 3min) in Laemli buffer and resolved by 10% SDS-PAGE. The resolved proteins were blotted onto nitrocellulose and studied using bioluminescence, donkey anti-rabbit-HRP (GE Healthcare) and donkey anti-goat-HRP (Merck Millipore) antibodies and the Clean Blot IP detection kit (Thermo Scientific). The ATP7B/AP-2α experiment was repeated two times.
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V vesicles. Cells treated for 3h with 100 nM BF and then with 40 µM Cu + and the drug for the times indicated, were stained for ATP7B, TGN38 and EEA1 and studied by microscopy (E-H).
Note the grape-surface of the cisternae loaded with ATP7B and its physical segregation as a distinct replica of the TGN38-positive cisterna (F, G), before its budding off into vesicles accompanied by the acquisition of the early endosome marker EEA1 (H). Arrowed areas are enlarged in the inserts in separate color channels. Bars 10 µm. Journal of Cell Science • Advance article Journal of Cell Science • Advance article 
